The European Medicines Agency took a decade too long to act on concerns about the cardiovascular safety of strontium ranelate and placed patients with osteoporosis at unnecessary risk, a recent review has claimed. Associate Professors Mark Bolland and Andrew Grey, from the University of Auckland, said documentation from 2006-07 showed that strontium ranelate increased the ...
Regulator criticised for inaction on strontium safety concerns
By Tony James
5 Oct 2016